Page last updated: 2024-10-30

lidoflazine and Vertigo

lidoflazine has been researched along with Vertigo in 1 studies

Lidoflazine: Coronary vasodilator with some antiarrhythmic action.

Vertigo: An illusion of movement, either of the external world revolving around the individual or of the individual revolving in space. Vertigo may be associated with disorders of the inner ear (EAR, INNER); VESTIBULAR NERVE; BRAINSTEM; or CEREBRAL CORTEX. Lesions in the TEMPORAL LOBE and PARIETAL LOBE may be associated with FOCAL SEIZURES that may feature vertigo as an ictal manifestation. (From Adams et al., Principles of Neurology, 6th ed, pp300-1)

Research Excerpts

ExcerptRelevanceReference
"During 6 months lidoflazine was applied ambulatorily in a dosage of 240 mg/a day orally in 21 patients after finished infarction."1.26[Clinical and ergometric studies on the effectiveness of lidoflazine in the treatment of chronic ischemic heart disease]. ( Lukesch, KH; Schäbitz, J; Schmeisser, M; Teichmann, W; Vogel, HC, 1976)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Teichmann, W1
Vogel, HC1
Schäbitz, J1
Schmeisser, M1
Lukesch, KH1

Other Studies

1 other study available for lidoflazine and Vertigo

ArticleYear
[Clinical and ergometric studies on the effectiveness of lidoflazine in the treatment of chronic ischemic heart disease].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1976, Mar-15, Volume: 31, Issue:6

    Topics: Animals; Blood Pressure; Chronic Disease; Coronary Disease; Dogs; Drug Evaluation; Drug Tolerance; E

1976